Este articulo es un Preprint
Los preprints son informes de investigación preliminares que no han sido certificados por revisión por pares. No deben considerarse para guiar la práctica clínica o los comportamientos relacionados con la salud y no deben publicarse en los medios como información establecida.
Los preprints publicados en línea permiten a los autores recibir comentarios rápidamente, y toda la comunidad científica puede evaluar de forma independiente el trabajo y responder adecuadamente. Estos comentarios se publican junto con los preprints para que cualquiera pueda leer y servir como una revisión pospublicación.
Clinical Laboratory Parameters Associated with Severe or Critical Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-analysis (preprint)
medrxiv; 2020.
Preprint
en Inglés
| medRxiv | ID: ppzbmed-10.1101.2020.04.24.20078782
ABSTRACT
Background:
To date, several clinical laboratory parameters associated with COVID-19 severity have been reported. However, these parameters have not been observed consistently across studies. The aim of this review was to assess clinical laboratory parameters which may serve as markers or predictors of severe or critical COVID-19 diseaseMethods:
We conducted a systematic search of MEDLINE, Embase, Web of Science, CINAHL and Google Scholar databases from 2019 through April 18, 2020, and reviewed bibliographies of eligible studies, relevant systematic reviews, and the medRxiv pre-print server. We included hospital-based observational studies reporting clinical laboratory parameters of confirmed cases of COVID-19 and excluded studies having large proportions (>10%) of children and pregnant women. Two authors independently carried out screening of articles, data extraction and quality assessment. Meta-analyses were done using random effects model. Meta-median difference (MMD) and 95% confidence interval (CI) was calculated for each laboratory parameter.Results:
Forty-five studies in 6 countries were included. Compared to non-severe COVID-19 cases, severe or critical COVID-19 disease was characterised by higher neutrophil count (MMD 1.23 [95% CI 0.58 to 1.88] x109 cells/L), and lower lymphocyte and CD4 counts with MMD (95% CI) of -0.39 (-0.47, -0.31) x109 cells/L and -204.9 (-302.6, -107.1) cells/l, respectively. Other notable results were observed for C-reactive protein (MMD 36.97 [95% CI 27.58, 46.35] mg/L), interleukin-6 (MMD 17.37 [95% CI 4.74, 30.00] pg/ml,), Troponin I (MMD 0.01 [0.00, 0.02] ng/ml), and D-dimer (MMD 0.65 [0.45, 0.85] mg/ml). Conclusions and Relevance Relative to non-severe COVID-19, severe or critical COVID-19 is characterised by increased markers of innate immune response, decreased markers of adaptive immune response, and increased markers of tissue damage and major organ failure. These markers could be used to recognise severe or critical disease and to monitor clinical course of COVID-19.
Texto completo:
Disponible
Colección:
Preprints
Base de datos:
medRxiv
Asunto principal:
Enfermedad Crítica
/
Neuropatía Mediana
/
COVID-19
/
Insuficiencia Multiorgánica
Idioma:
Inglés
Año:
2020
Tipo del documento:
Preprint
Similares
MEDLINE
...
LILACS
LIS